Skip to content

Clinical study of guanxining tablet in the treatment of rheumatoid arthritis with cardiovascular damage

Clinical study of guanxining tablet in the treatment of rheumatoid arthritis with cardiovascular damage

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030247
Enrollment
Unknown
Registered
2020-02-26
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus

Interventions

Sponsors

Zhejinag University of f Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) meet the diagnostic criteria of RA, activity period and abnormal heart function; (2) between the ages of 18 and 60; (3) if taking NSAIDs, the dose has been stable for at least 4 weeks; if not, it has been stable for at least 1 week; (4) if you take MTX, you have been treated with MTX3 for at least 4 months, and the dose is fixed at 10mg/ week for at least 4 weeks.If you take LEF, you have been treated with leff for at least 3 months, and the dose is fixed at 10mg/ day for at least 4 weeks. (5) if glucocorticoid is taken, the dose (compared with prednisone) must be less than 15mg/ day and has been used for at least 4 weeks; (6) participate in the study voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) intramuscular injection or intravenous drip of glucocorticoids within 4 weeks; (2) das28-3 score > 5.1 (high activity); (3) patients with other rheumatic diseases such as systemic lupus erythematosus, sjogren's syndrome and gout; (4) pregnant or nursing women or those who plan to give birth in the near future; (5) allergic to the test drugs; (6) those who have participated in other clinical trials recently (within 1 month); (7) mental patients and people without capacity for civil conduct.

Design outcomes

Primary

MeasureTime frame
SLEDAI;

Countries

China

Contacts

Public ContactWang Wei-jie
jack1987168@163.com+86 18072946549

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026